Last reviewed · How we verify
Semaglutide J
Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, promote satiety, and slow gastric emptying.
Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, promote satiety, and slow gastric emptying. Used for Type 2 diabetes mellitus, Chronic weight management in adults with obesity or overweight.
At a glance
| Generic name | Semaglutide J |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes, Obesity |
| Phase | Phase 3 |
Mechanism of action
Semaglutide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also acts on central and peripheral GLP-1 receptors to reduce appetite, increase feelings of fullness, and slow gastric emptying, leading to reduced caloric intake and improved glycemic control. The drug has demonstrated cardiovascular and weight loss benefits beyond glucose lowering.
Approved indications
- Type 2 diabetes mellitus
- Chronic weight management in adults with obesity or overweight
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Headache
- Fatigue
Key clinical trials
- A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes (PHASE3)
- A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants (PHASE1)
- A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV (PHASE1)
- A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Semaglutide J CI brief — competitive landscape report
- Semaglutide J updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI